NCT05836896View on ClinicalTrials.gov

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
NeoplasmsRelapsed Diffuse Large B-cell Lymphoma (DLBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)Multiple Myeloma, RefractoryMultiple Myeloma in Relapse
Interventions
GENETIC

MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy

Trial Locations (1)

01307

RECRUITING

Technische Universität Dresden, NCT/UCC, Early Clinical Trial Unit, Dresden

All Listed Sponsors
collaborator

German Cancer Research Center

OTHER

lead

Technische Universität Dresden

OTHER